Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.800
-0.110 (-5.76%)
Feb 21, 2025, 4:00 PM EST - Market closed
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Akebia Therapeutics stock has a target of 7.50, which predicts an increase of 316.67% from the current stock price of 1.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 23, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Akebia Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +316.67% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +316.67% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +316.67% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +316.67% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +316.67% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
154.06M
from 194.62M
Decreased by -20.84%
Revenue Next Year
183.81M
from 154.06M
Increased by 19.31%
EPS This Year
-0.31
from -0.28
EPS Next Year
-0.16
from -0.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 165.0M | 206.0M | 261.2M | |||
| Avg | 154.1M | 183.8M | 250.3M | |||
| Low | 144.2M | 164.1M | 237.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -15.2% | 33.7% | 42.1% | |||
| Avg | -20.8% | 19.3% | 36.2% | |||
| Low | -25.9% | 6.5% | 29.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.27 | 0.08 | 0.42 | |||
| Avg | -0.31 | -0.16 | 0.11 | |||
| Low | -0.33 | -0.34 | -0.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.